Literature DB >> 36104286

Identification of a transcriptional signature found in multiple models of ASD and related disorders.

Samuel Thudium1,2, Katherine Palozola1,2, Éloïse L'Her1,2, Erica Korb1,2.   

Abstract

Epigenetic regulation plays a critical role in many neurodevelopmental disorders (NDDs), including autism spectrum disorder (ASD). In particular, many such disorders are the result of mutations in genes that encode chromatin-modifying proteins. However, although these disorders share many features, it is unclear whether they also share gene expression disruptions resulting from the aberrant regulation of chromatin. We examined five chromatin modifiers that are all linked to ASD despite their different roles in regulating chromatin. Specifically, we depleted ASH1L, CHD8, CREBBP, EHMT1, and NSD1 in parallel in a highly controlled neuronal culture system. We then identified sets of shared genes, or transcriptional signatures, that are differentially expressed following loss of multiple ASD-linked chromatin modifiers. We examined the functions of genes within the transcriptional signatures and found an enrichment in many neurotransmitter transport genes and activity-dependent genes. In addition, these genes are enriched for specific chromatin features such as bivalent domains that allow for highly dynamic regulation of gene expression. The down-regulated transcriptional signature is also observed within multiple mouse models of NDDs that result in ASD, but not those only associated with intellectual disability. Finally, the down-regulated transcriptional signature can distinguish between control and idiopathic ASD patient iPSC-derived neurons as well as postmortem tissue, demonstrating that this gene set is relevant to the human disorder. This work identifies a transcriptional signature that is found within many neurodevelopmental syndromes, helping to elucidate the link between epigenetic regulation and the underlying cellular mechanisms that result in ASD.
© 2022 Thudium et al.; Published by Cold Spring Harbor Laboratory Press.

Entities:  

Year:  2022        PMID: 36104286      PMCID: PMC9528985          DOI: 10.1101/gr.276591.122

Source DB:  PubMed          Journal:  Genome Res        ISSN: 1088-9051            Impact factor:   9.438


  91 in total

1.  NSD1 mutations are the major cause of Sotos syndrome and occur in some cases of Weaver syndrome but are rare in other overgrowth phenotypes.

Authors:  Jenny Douglas; Sandra Hanks; I Karen Temple; Sally Davies; Alexandra Murray; Meena Upadhyaya; Susan Tomkins; Helen E Hughes; Trevor R P Cole; Nazneen Rahman
Journal:  Am J Hum Genet       Date:  2002-12-02       Impact factor: 11.025

2.  Chd8 Mutation Leads to Autistic-like Behaviors and Impaired Striatal Circuits.

Authors:  Randall J Platt; Yang Zhou; Ian M Slaymaker; Ashwin S Shetty; Niels R Weisbach; Jin-Ah Kim; Jitendra Sharma; Mitul Desai; Sabina Sood; Hannah R Kempton; Gerald R Crabtree; Guoping Feng; Feng Zhang
Journal:  Cell Rep       Date:  2017-04-11       Impact factor: 9.423

Review 3.  Cdks, cyclins and CKIs: roles beyond cell cycle regulation.

Authors:  Shuhui Lim; Philipp Kaldis
Journal:  Development       Date:  2013-08       Impact factor: 6.868

4.  CHD8 is an ATP-dependent chromatin remodeling factor that regulates beta-catenin target genes.

Authors:  Brandi A Thompson; Véronique Tremblay; Grace Lin; Daniel A Bochar
Journal:  Mol Cell Biol       Date:  2008-03-31       Impact factor: 4.272

5.  Abnormal skeletal patterning in embryos lacking a single Cbp allele: a partial similarity with Rubinstein-Taybi syndrome.

Authors:  Y Tanaka; I Naruse; T Maekawa; H Masuya; T Shiroishi; S Ishii
Journal:  Proc Natl Acad Sci U S A       Date:  1997-09-16       Impact factor: 11.205

Review 6.  Alternative functions of core cell cycle regulators in neuronal migration, neuronal maturation, and synaptic plasticity.

Authors:  Christopher L Frank; Li-Huei Tsai
Journal:  Neuron       Date:  2009-05-14       Impact factor: 17.173

7.  Reduced fear and aggression and altered serotonin metabolism in Gtf2ird1-targeted mice.

Authors:  E J Young; T Lipina; E Tam; A Mandel; S J Clapcote; A R Bechard; J Chambers; H T J Mount; P J Fletcher; J C Roder; L R Osborne
Journal:  Genes Brain Behav       Date:  2007-08-03       Impact factor: 3.449

8.  Patterns and rates of exonic de novo mutations in autism spectrum disorders.

Authors:  Benjamin M Neale; Yan Kou; Li Liu; Avi Ma'ayan; Kaitlin E Samocha; Aniko Sabo; Chiao-Feng Lin; Christine Stevens; Li-San Wang; Vladimir Makarov; Paz Polak; Seungtai Yoon; Jared Maguire; Emily L Crawford; Nicholas G Campbell; Evan T Geller; Otto Valladares; Chad Schafer; Han Liu; Tuo Zhao; Guiqing Cai; Jayon Lihm; Ruth Dannenfelser; Omar Jabado; Zuleyma Peralta; Uma Nagaswamy; Donna Muzny; Jeffrey G Reid; Irene Newsham; Yuanqing Wu; Lora Lewis; Yi Han; Benjamin F Voight; Elaine Lim; Elizabeth Rossin; Andrew Kirby; Jason Flannick; Menachem Fromer; Khalid Shakir; Tim Fennell; Kiran Garimella; Eric Banks; Ryan Poplin; Stacey Gabriel; Mark DePristo; Jack R Wimbish; Braden E Boone; Shawn E Levy; Catalina Betancur; Shamil Sunyaev; Eric Boerwinkle; Joseph D Buxbaum; Edwin H Cook; Bernie Devlin; Richard A Gibbs; Kathryn Roeder; Gerard D Schellenberg; James S Sutcliffe; Mark J Daly
Journal:  Nature       Date:  2012-04-04       Impact factor: 49.962

9.  Sporadic autism exomes reveal a highly interconnected protein network of de novo mutations.

Authors:  Brian J O'Roak; Laura Vives; Santhosh Girirajan; Emre Karakoc; Niklas Krumm; Bradley P Coe; Roie Levy; Arthur Ko; Choli Lee; Joshua D Smith; Emily H Turner; Ian B Stanaway; Benjamin Vernot; Maika Malig; Carl Baker; Beau Reilly; Joshua M Akey; Elhanan Borenstein; Mark J Rieder; Deborah A Nickerson; Raphael Bernier; Jay Shendure; Evan E Eichler
Journal:  Nature       Date:  2012-04-04       Impact factor: 49.962

10.  BET protein Brd4 activates transcription in neurons and BET inhibitor Jq1 blocks memory in mice.

Authors:  Erica Korb; Margo Herre; Ilana Zucker-Scharff; Robert B Darnell; C David Allis
Journal:  Nat Neurosci       Date:  2015-08-24       Impact factor: 24.884

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.